Anavex Life Sciences Corp. (AVXL) Balance Sheet
As of 2026-06-30 (10-Q), Anavex Life Sciences Corp. (AVXL) reported total assets of $120.1M, total liabilities of $7.7M and shareholders' equity of $112.4M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $118.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVXLAnavex Life Sciences Corp.Follow AVXL — free
—
Price chart with a free account
- Market cap
- 123.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 23 Nov, in 30 days
| Line | FY2011 Sep 11 | FY2012 Sep 12 | FY2013 Sep 13 | FY2014 Sep 14 | FY2015 Sep 15 | FY2016 Sep 16 | FY2017 Sep 17 | FY2018 Sep 18 | FY2019 Sep 19 | FY2020 Sep 20 | FY2021 Sep 21 | FY2022 Sep 22 | FY2023 Sep 23 | FY2024 Sep 24 | FY2025 Sep 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | — | — | 9.2 | 27.4 | 22.9 | 22.2 | 29.2 | 152.1 | 149.2 | 151.0 | 132.2 | 102.6 | 118.3 | |
| Current assets | 0.2 | 0.0 | 0.4 | 7.4 | 15.5 | 9.4 | 27.8 | 26.1 | 25.3 | — | — | — | — | — | — | — | |
| Total assets | 0.2 | 0.0 | 0.4 | 7.4 | 15.5 | 9.5 | 27.8 | 26.2 | 25.3 | 34.5 | 161.6 | 152.7 | 154.4 | 135.6 | 103.8 | 120.1 | |
| Current liabilities | — | 2.9 | 2.0 | 1.4 | 2.7 | 3.2 | 3.6 | 3.9 | 5.0 | 7.3 | 10.8 | — | — | — | — | — | |
| Long-term debt | — | — | — | 5.7 | 0.0 | — | — | — | — | — | — | — | — | — | — | — | |
| Total liabilities | 1.3 | 2.9 | 2.9 | 7.2 | 2.7 | 3.2 | 3.6 | — | 5.0 | 7.3 | 10.8 | 10.2 | 12.5 | 15.3 | 8.9 | 7.7 | |
| Shareholders' equity | -1.1 | -2.9 | -2.5 | 0.2 | 12.8 | 6.3 | 25.9 | 22.3 | 20.3 | 27.2 | 150.8 | 142.5 | 141.9 | 120.3 | 94.9 | 112.4 |
USD millions · SEC XBRL
Anavex Life Sciences Corp. — questions
- How much cash does Anavex Life Sciences Corp. have?
- $118.3M in cash and cash equivalents as of 2026-06-30.
- What are Anavex Life Sciences Corp.'s total assets?
- $120.1M as of 2026-06-30.
- What is Anavex Life Sciences Corp.'s shareholders' equity?
- $112.4M as of 2026-06-30.
Every figure on this page comes from Anavex Life Sciences Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.